What is Global WholeHealth Partners Corporation (GWHP)?

Global WholeHealth Partners Corporation (GWHP) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of GWHP?

The current price of GWHP is $0.00. Prices are updated in real time on Stocks360.

What is GWHP's price-to-earnings (PE) ratio?

GWHP's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is GWHP's market capitalization?

GWHP's market capitalization is $1,313.00, placing it in the small-cap tier.

Global WholeHealth Partners Corporation (GWHP)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$0.00

Market Cap

$1.31K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-11.47

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

103.30K

Global WholeHealth Partners Corporation (GWHP) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $1.31K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Global WholeHealth Partners Corporation

Global WholeHealth Partners Corporation, established in 2013 and based in San Clemente, California, is dedicated to the development and distribution of a diverse array of in-vitro diagnostic test kits across the United States. The company provides swift diagnostic solutions, including rapid assays for CoVid-19, whole blood Ebola, whole blood Zika, and whole blood tuberculosis (TB), among other tests. These diagnostic tools are designed for wide accessibility, catering to both over-the-counter consumer purchases and professional point-of-care settings such as hospitals, physicians' offices, and various medical clinics. Their product line effectively identifies a multitude of diseases, encompassing infections like Ebola, Zika, dengue, malaria, influenza, tuberculosis, coronaviruses, and other conditions transmitted by vectors.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.18×
P/B	-0.00×
PEG	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	-0.17×
EV / Sales	94.03×
Earnings Yield	-548959.05%
Free Cash Flow Yield	-149901.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$693.44K
Revenue (TTM)	$7.38K
Net Income (TTM)	-$7.21M
Free Cash Flow (TTM)	-$998.88K
Net Debt	$692.13K
Working Capital	-$1.58M
Gross Margin	-1518.64%
Operating Margin	-56759.32%
Net Margin	-69898.31%
Return on Equity	618.63%
Return on Invested Capital	477.11%